Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.

Rhythm Pharmaceuticals Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rhythm Pharmaceuticals (RYTM) and Cardiff Oncology (...

Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM) and Cardiff Oncology (CRDF)

In a report released today, Seamus Fernandez from Guggenheim reiterated a Buy rating on Rhythm Pharmaceuticals, with a price target of $143.00. Acc...

Guggenheim Remains a Buy on Rhythm Pharmaceuticals (RYTM)

In a report released on May 8, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Rhythm Pharmaceuticals, with a price target of $133.00....

Stifel Nicolaus Remains a Buy on Rhythm Pharmaceuticals (RYTM)

Rhythm Pharmaceuticals (($RYTM)) has held its Q1 earnings call. Read on for the main highlights of the call. Rhythm Pharmaceuticals’ latest earning...

Rhythm Pharmaceuticals Bets Big On Obesity Growth

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ascendis Pharma (ASND) and Rhythm Pharmaceuticals (R...

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND) and Rhythm Pharmaceuticals (RYTM)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Rhythm Pharmaceuticals (RYTM), LeonaBio (LONA) and u...

Analysts’ Top Healthcare Picks: Rhythm Pharmaceuticals (RYTM), LeonaBio (LONA)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tonix Pharma (TNXP), Crescent Biopharma (CBIO) and R...

Market Cap	$6.84B	P/E Ratio	N/A
52W High	$122.20	52W Low	$58.71
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	3.6%	52W Position	48.5%
Overall Score	46	Value Score	40
Quality Score	78	Technical Score	20

EPS Current Est	$-3.18	EPS Next Est	$-0.66
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RYTM	$89.49	+1.88%	81.91K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RYTM	$89.49	+1.9%	81.91K
3
4
5
6

RYTM

RYTM

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Rhythm Pharmaceuticals Inc. Data in Excel

Get Rhythm Pharmaceuticals Inc. Data in Excel